chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Had a little bit of discomfort; Developed a really funny rash under her left arm that was wide, dark and hurting; Developed a really funny rash under her left arm that was wide, dark and hurting; Developed a really funny rash under her left arm that was wide, dark and hurting; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE DISCOMFORT (Had a little bit of discomfort), VACCINATION SITE DISCOLOURATION (Developed a really funny rash under her left arm that was wide, dark and hurting), VACCINATION SITE PAIN (Developed a really funny rash under her left arm that was wide, dark and hurting) and VACCINATION SITE RASH (Developed a really funny rash under her left arm that was wide, dark and hurting) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     Concomitant products included ATORVASTATIN for an unknown indication.    On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced VACCINATION SITE DISCOMFORT (Had a little bit of discomfort), VACCINATION SITE DISCOLOURATION (Developed a really funny rash under her left arm that was wide, dark and hurting), VACCINATION SITE PAIN (Developed a really funny rash under her left arm that was wide, dark and hurting) and VACCINATION SITE RASH (Developed a really funny rash under her left arm that was wide, dark and hurting). At the time of the report, VACCINATION SITE DISCOMFORT (Had a little bit of discomfort), VACCINATION SITE DISCOLOURATION (Developed a really funny rash under her left arm that was wide, dark and hurting), VACCINATION SITE PAIN (Developed a really funny rash under her left arm that was wide, dark and hurting) and VACCINATION SITE RASH (Developed a really funny rash under her left arm that was wide, dark and hurting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
weakness, falling  Narrative: Patient is a 76yo male who was contacted by phone and reports  that on Friday afternoon March 13th felt weak and fell, went to ER after falling 5x,  also felt muscle weakness 'like I had rheumatic fever when I was a kid'; daughter  came home and took him to local ER. Received 2nd of 2 part  covid vaccine on March 11th at Health Care Center, thought to have reaction to vaccine. Next  morning felt mild temp and then symptoms progressed to the point of weakness in  legs causing him to fall; rapid heart rate 100-140s noted in hospital, back to  normal during stay. Discharged from hospital on Sunday March 14th 2021.
earache (ear pain); Low grade fever (pyrexia); chills; headache; joint pain (arthralgia); This is a spontaneous report from a contactable consumer (patient). A 40-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EN5318), via an unspecified route of administration, administered in the right arm on 19Feb2021 12:00 (at the age of 40-year-old) as single dose for covid-19 immunisation. Medical history included intravenous iodine allergy. The patient was not diagnosed with covid-19 prior to vaccination, did not receive any other vaccines within 4 weeks prior to the covid vaccine, and did not received any other medications within two weeks of vaccination. The patient's concomitant medications were not reported. The patient previously received first dose of BNT162B2 (lot number: EN5318), via unspecified route of administration in the right arm on 27Jan2021 for COVID19 immunisation. The patient experienced earache (ear pain), low grade fever (pyrexia), chills, headache, joint pain (arthralgia) on 20Feb2021 at 02:00 am. The patient did not receive any treatment for the events. Since the vaccination, the patient has not been tested for COVID-19. The patient recovered from earache (ear pain), low grade fever (pyrexia), chills, headache, joint pain (arthralgia) on an unspecified date.   No follow-up attempts are needed. No further information is expected.
tinnitus developed in one ear 4 days after the vaccination.  Otherwise patient 100% healthy. Never had any hearing issues.
Initial report received on 3/29/2006 from a health care provider. A 31 year old male with no significant medical history, had received his first intramuscular injection of DECAVAC, lot number U1576DA, in the left deltoid, his first intra dermal injection of Tubersol 5 TU, lot number C1710AA, in the right fore arm and his first intra muscular injection of another manufactures Hepatitis B vaccine, lot number 0504R in the left deltoid on 2/23/2006 at 14:15. 180 seconds later, he experienced syncope, muscle contractions of the hands, feet and legs and laryngeal spasm. The patient had recovered at the time of this report.
Pt recv vax on 10/27/98; on same day pt exp pain in arm & decreased movement; tx=Ibuprofen, cold compress
red round itchy raised lesion on arm at site of vaccine, delayed reaction, no fever or chills, no pain in arm. Size of a grapefruit. numbness down arm to thumb and first 2 fingers.
Severe arm pain, nausea, vomiting, chills without fever, bone pain and headache.
This spontaneous report as received from a Registered Nurse refers to 2 patients of unknown demographics. The patient's medical history and current conditions were not reported. On 24-SEP-2014 the 2 patients were inadvertently administered improperly stored RECOMBIVAX HB injection 10Y (strength, dose and frequency not reported) (lot # and expiry date not reported. No adverse effects reported. Product quality complaint was not involved.  This is one of several reports received from the same source.  Follow up information has been received from the Registered Nurse refers to a 1 day old patient (previously reported as 2 patients). On 24-SEP-2014 the patient was vaccinated with improperly stored RECOMBIVAX HB (lot # K006682, expiry date 17-DEC-2015). Additional information has been requested.
This spontaneous report was received on 26-OCT-2015 from a registered nurse concerning a patient of unknown age and gender who on 21-OCT-2009 was administered the primary dose of VAQTA two-dose series. On 26-OCT-2015, the patient was administered the booster dose but it was expired (lot number K008984; expiration 21-OCT-2015). No adverse events were reported. Additional information has been requested.
This spontaneous report was received from a medical assistant regarding a patient of unknown date and gender. Information on their concurrent conditions, pertinent medical history and drug allergies were not reported. On 15-MAR-2016, the patient was vaccinated with improperly stored (Merck) VARIVAX lot # L026405, expiry date 15-JUL-2017 (dose, frequency, route and anatomical location were not reported) (incorrect product storage). Concomitant medication were not reported. No adverse effects were reported. There were no Product Quality Concern (PQC) involved. Temperature at which the administered product  was stored was 9.3 Fahrenheit, there were no previous temperature excursions performed. This is one of several reports received from the same reporter. Additional information has been requested.
Initial information received from a healthcare professional on 02 January 2014. A patient, whose demographics, medical history and concomitant medications were unknown, had received a dose of TDAP (batch number, dose number, route and anatomical site of administration unknown) on an unspecified date of April 2013. It was reported that on an unspecified date, the injection site had become swollen, sore and tender. Laboratory data and corrective medications were unknown. The patient outcome was unknown. Documents held by sender: None.
She got very sick, was already not feeling well before vaccine.  She died may 15, 2021.
Patient received Moderna COVID vaccine on 2/4/21 (lot # 013M20A), 3/4/21 (lot # 029A21A), and 10/22/21 (lot # 026D21A).  On 3/20/22, patient admitted to our inpatient facility with COVID-19 infection and progressive worsening  generalized weakness (unable to ambulate) due to acute illness. As of today (3/24/22), patient is still admitted in the med/surg unit.
A report has been received from a Health Professional concerning a 4 year old unknown gender patient. No information was provided regarding the concomitant medications, concurrent diseases and medical history of the patient. Nurse reported patient developed hives after dose of last year FLUMIST quadrivalent (intranasal). Action taken with FLUMIST quadrivalent was unknown. The outcome of the event of hives was unknown. The report was considered to be non-serious by company physician.
pt recvd vax; pt devel red areas & nodules at inject site,lasting 2 wks or longer; pt exp rxn dec93 following immun; recovered
4 different individuals sent to the emergency room for body rashes and hives.; 4 different individuals sent to the emergency room for body rashes and hives.; This is a spontaneous report from a contactable pharmacist. This pharmacist reported similar events for 4 patients. This is a second of four reports. A patient of unspecified age and gender received BNT162B2 (lot/batch number and expiration date not provided), via an unspecified route of administration on an unspecified date at single dose for immunization. Medical history included allergies to bee stings from an unknown date. The patient's concomitant medications were not reported. The patient was sent to the emergency room for body rashes and hives. They are recommending that those with a bee sting allergy hold off until they know more. The outcome of the events was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2020502532 same reporter, event and drug but different patient
I felt dizzy; nauseated; This is a spontaneous report from a non-contactable consumer (patient). This 65-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) (Lot# EL9261), via an unspecified route of administration on 20Jan2021 14:15 at single dose on the right arm for COVID-19 immunization. The patient medical history was none. No known allergies. The patient's concomitant medications were not reported. No other vaccine received in four weeks. Within 15 mins of being vaccinated, patient felt dizzy and nauseated. Patient believed these symptoms would have been less severe had she eaten something and drunk sufficient fluids prior to the injection. The symptoms went away within a couple of hours after eating and drinking. No COVID prior vaccination. No COVID tested post vaccination. No treatment received. Outcome of the events was recovered in Jan2021.  No follow-up attempts are possible. No further information is expected.
temperature excursion on GARDASIL 9; No other adverse events - No signs or symptoms reported; Information has been received from a nurse reporting on a patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history or concomitant medication.  On an unknown date, the patient was vaccinated with an improperly stored dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 mL for prophylaxis, lot# 1687293 and expiration date reported as 25-AUG-2022, but upon internal validation was established as 30-APR-2023 (route of administration not reported). No adverse events were reported.  On an unknown date, the vaccine underwent a temperature excursion of 47.1 Fahrenheit degree for 13 minutes. No previous temperature excursions were reported. The call was not placed because a digital data logger.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: 1687293; expirationdate: 30-APR-2023; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-2103USA005285: US-009507513-2104USA003211: US-009507513-2104USA003213: US-009507513-2104USA003214: US-009507513-2104USA003215: US-009507513-2104USA003216: US-009507513-2104USA003217: US-009507513-2104USA003218: US-009507513-2104USA003219: US-009507513-2104USA003220: US-009507513-2104USA003221: US-009507513-2104USA003222: US-009507513-2104USA003223: US-009507513-2104USA003224: US-009507513-2104USA003225: US-009507513-2104USA003196: US-009507513-2104USA003197: US-009507513-2104USA003198: US-009507513-2104USA003199: US-009507513-2104USA003200: US-009507513-2104USA003201: US-009507513-2104USA003202: US-009507513-2104USA003203: US-009507513-2104USA003204: US-009507513-2104USA003205: US-009507513-2104USA003206: US-009507513-2104USA003210: US-009507513-2104USA003207: US-009507513-2104USA003208: US-009507513-2104USA003209:
Employee had redness, swelling, soreness, and itching at site of vaccination. Denied:  SOA, tightness in throat, itching on tongue, or difficulty swallowing. Ice to area gave some relief.  Employee to contact PCP about use of OTC antihistamines if needed. No further action required as symptoms not getting any worse.
The cough has actually gotten worse because it is constant now and it is a dry cough; Buildup of mucous in the back of her throat; This is a spontaneous report from a contactable consumer or other non hcp (patient herself). A 63-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection), via an unspecified route of administration, administered in arm left on 02Apr2021 (at the age of 63-year-old) (Batch/Lot Number: ER2613) as single dose for COVID-19 immunisation. Medical history included hypertension. Concomitant medications included high blood pressure medications. The patient was allergic to egg in one of them it had like eggs or dairy or something and she had a reaction or something like that. Previously the patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection), via an unspecified route of administration, administered in arm left on 12Mar2021 (at the age of 63-year-old) (Batch/Lot Number: EN6206) as single dose for COVID-19 immunisation and experienced cough. On an unspecified date in 2021, the patient experienced cough had actually gotten worse because it was constant now and it was a dry cough and buildup of mucous in the back of her throat. She had already been to two doctors, her primary care and her heart doctor, and they were trying to figure out why she still had symptoms and increased symptoms since she had the shot. They cannot really figure it out, they assumed it was her medicine, so they took her off medicines she was on. She was still having a cough and it was pretty bad and there was a buildup of mucous in the back of her throat. It was constant and it was a dry cough. She guessed she did not know where else to go at this point because she still had these symptoms, and she did not know what to do for them to go away. Caller states she was taking cough medicine and throat lozenges and it was not going away. She wanted to get over this. The only treatment was over the counter medicines, all kinds of cough drops, all kinds of lozenges and things like that to alleviate it a little. Caller added after the second vaccine, she felt it more. She did notice a little side effect after the first but more after the second. The events did not require a visit to Emergency Room but visited to physician office. No prior vaccinations received within 4 weeks. she was not had this cough before. The reporter considered the event to as non-serious. Caller went and got two COVID tests after, one afterward and one before. It was negative. Both were negative and the last one was a week ago. Therapeutic measures were taken as result of the cough has actually gotten worse because it was constant now and it was a dry cough, buildup of mucous in the back of her throat. The patient underwent lab tests and procedures which included sars-cov-2 test: negative on an unspecified date, nasal swabs, sars-cov-2 test: negative on an unspecified date in Jun2021 nasal swabs. The outcome of the events was not recovered.  No follow up attempts are possible. No further information is expected.
Intense vertigo, followed by nausea, and vomiting and defecation. This happened three times upon awakening.; Intense vertigo, followed by nausea, and vomiting and defecation. This happened three times upon awakening.; Intense vertigo, followed by nausea, and vomiting and defecation. This happened three times upon awakening.; Intense vertigo, followed by nausea, and vomiting and defecation. This happened three times upon awakening.; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 15:30 (age at vaccination unknown) as a single dose for COVID-19 immunisation. The patient previously had penicillin and experienced penicillin allergy. The patient did not receive any medication within two weeks prior to vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6207) via an unspecified route of administration in the left arm on 15Mar2021 at 15:30 (age at vaccination unknown) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021, the patient experienced intense vertigo, followed by nausea, and vomiting and defecation. This had happened three times upon awakening. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of intense vertigo, followed by nausea, and vomiting and defecation and included rest, and being stationary. The clinical outcome of the events intense vertigo, followed by nausea, and vomiting and defecation was unknown at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
patient states he is still having neurological pain  and can't lift anything 2 months after receiving vaccine. Patient reports it is severely impacting his quality of life.
Vaccine was administered in the incorrect muscle/location. Consulted (unofficially) with physicians a nurses, who confirmed location was indeed incorrect. Vaccine was administered below the deltoid muscle and in the ?groove? or ?dip? where less muscle is present, located below the deltoid, and seemingly between the bicep and tricep muscles. It is not obvious which muscle the needle penetrated (if any), since the needle penetrated the area below the deltoid and not in an obvious muscle group.
I started sweating immediately and it continued through the night and had a fever for 101 and lasted the whole next day. I had body aches I couldn't get out of bed and bad fatigue.  Three days later my left thumb went completely numb and tingly. The Dr. said that patients had reported this and could last up to four months to go away. My left foot went numb a week later and lasted a 1/2 hour. On March 4, both my hands went numb while I was driving and lasted about 45 minutes.  The left food has gone numb off and on.
This spontaneous report as received from a nurse refers to a 46 year old female patient. On 06-NOV-2015 the patient was vaccinated with a dose of GARDASIL. No adverse effect reported. Additional information has been requested.
Chills; fever going from 99 to 100 and back down again; very achy; A Spontaneous report was reported was received from concerning a 78 years old, male patient who was administered by Modern's COVID-19 vaccine and an adverse event was reported.  The patient's medical history was not known and patient is having questions regarding the use of Tylenol whether they should take it or what they can do.  On 22 Jan 2021 ,of morning  both patient and his wife received Moderna vaccine.   On 23rd JAN  2021 patient reported severe chills and has a fever which went from 99 to 100 back down again . Patient was confused and don't know what to do. They both were very achy. Lot number 20A (patient didn't provided the rest of the lot number.  No treatment information was provided.  The adverse event ,reported by the patient was considered to be resolved.
Axillary adenopathy from second shot on left arm that has last more than 3 weeks; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 19Apr2021 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included hashimoto's disease and gitelman's syndrome. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on an unknown date, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021, the patient experienced axillary adenopathy from second shot on left arm that lasted more than 3 weeks, left arm was injection site. The doctor prescribed prednisone to the patient and if adenopathy is not down in one week after steroid, the doctor would order an axillary ultrasound. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event which included treatment with prednisone. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event axillary adenopathy from second shot on left arm that lasted more than 3 weeks was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
lost of taste; chills (cold and hot); getting cold and hot; lack of energy; feeling nauseous; This is a spontaneous report from a contactable consumer or other non hcp. A 53-years-old female patient received bnt162b2 (Pfizer-Biontech Covid-19 Vaccine, formulation: solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 28Jun2021 (at the age of 53-years-old) as dose 1, single for covid-19 immunisation. Medical history included diabetes mellitus wife is diabetic. The patient's concomitant medications were not reported. On 28Jun2021, the patient experienced lost of taste, chills, getting hot and cold, lack of energy, feeling nauseous. The outcome of the events was unknown.